New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
07:32 EDTLGND, GSKGlaxoSmithKline granted Breakthrough Therapy designation for Promacta/Revolade
Ligand Pharmaceuticals (LGND) announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline Breakthrough Therapy designation for Promacta/Revolade for the treatment of cytopenias in patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy. The Breakthrough Therapy designation was based on the results from an open-label, Phase II National Institute of Health study of eltrombopag in 43 heavily pre-treated SAA patients with an insufficient response to IST.
News For LGND;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
11:32 EDTLGNDLigand reports Pfizer receives EU marketing authorization for Duavive
Ligand Pharmaceuticals (LGND) announced that its partner Pfizer (PFE) has received EU marketing authorization for DUAVIVE from the European Commission. In the EU, DUAVIVE is indicated for the treatment of estrogen deficiency symptoms in postmenopausal women with a uterus for whom treatment with progestin-containing therapy is not appropriate. Ligand will be entitled to a milestone payment following Pfizer obtaining pricing of DUAVIVE in a major European market, the company stated.
December 18, 2014
09:21 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
07:15 EDTGSKAgenus reports GSK ZOE-50 Phase 3 study met primary endpoint
Subscribe for More Information
December 9, 2014
10:23 EDTGSKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTGSKARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:44 EDTGSKAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:37 EDTGSKGlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.
December 8, 2014
13:32 EDTGSKEpizyme announces results for PRMT5 inhibitor
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use